Tyme Technologies Inc. (Nasdaq: TYME) to Ring The Nasdaq Stock Market Opening Bell
August 07 2017 - 10:31AM
What:Tyme Technologies Inc. (Nasdaq:TYME), a
clinical stage biotechnology company developing novel cancer
therapeutics to address multiple tumor types, will visit the Nasdaq
MarketSite in Times Square in celebration of their recent IPO.
On Facebook: https://www.facebook.com/tymetechnologiesOn
LinkedIn: https://www.linkedin.com/company-beta/11139295/
In honor of the occasion, Tyme Co-founders Steven
Hoffman, CEO & Chief Science Officer, and
Michael Demurjian, Chief Operating Officer, will
ring the Opening Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd
& Broadway – Broadcast Studio
When:Tuesday, August 8, 2017 – 9:15 a.m. to
9:30 a.m. ET
Tyme Technologies Inc. Media Contact:James
Heins/ICR203-856-2121james.heins@icrinc.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Opening
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Open, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market open of your choice.
About Tyme Tyme Inc. is a clinical-stage
biotechnology company developing cancer therapeutics that are
intended to be broadly effective across tumor types and have low
toxicity profiles. Unlike targeted therapies that attempt to
regulate specific mutations within cancer, our therapeutic approach
is designed to take advantage of a cancer cell’s innate metabolic
weaknesses to compromise its defenses, leading to cell death
through oxidative stress and exposure to the body’s natural immune
system. Our lead clinical program, SM-88, is a first-in-class
combination therapy in Phase II development for prostate cancer,
and we are preparing to initiate an additional Phase II clinical
trial for pancreatic cancer. For more information, visit our
website: www.tymeinc.com.
About NasdaqNasdaq (Nasdaq:NDAQ) is a leading
global provider of trading, clearing, exchange technology, listing,
information and public company services. Through its diverse
portfolio of solutions, Nasdaq enables customers to plan, optimize
and execute their business vision with confidence, using proven
technologies that provide transparency and insight for navigating
today's global capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 90
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to approximately 3,900 total listings
with a market value of approximately $12 trillion. To learn more,
visit: http://business.nasdaq.com
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2023 to Apr 2024